Clinical management of mantle cell lymphoma in the elderly

References

• Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012;87:605–609.
   Web of Science ®Google Scholar
• Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology. 2009;23:683–690.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82:78–101.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. WHO Classification of Tumours. 2017. Revised 4th edition. 2:288.
   Google Scholar
• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750–762.
   PubMed Web of Science ®Google Scholar
• Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008;112(3):822–829.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109(11):4599–4606.
   PubMed Web of Science ®Google Scholar
• Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 2009;113(13):3059–3069.
   PubMed Web of Science ®Google Scholar
• Bienvenu F, Jirawatnotai S, Elias JE, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010;463:374–378.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315–4321.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Royo C, Caravajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma. Blood. 2013;121(8):1394–1402.
   PubMed Web of Science ®Google Scholar
• Vogt N, Dai B, Erdmann T, et al. The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma. 2017;58(7):1530–1537.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–1562.
   PubMed Web of Science ®Google Scholar
• Magne J, Jenvrin A, Chauchet A, et al. Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. Exp Hematol Oncol. 2018;20; 7:5.
   Google Scholar
• Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250–18255.
   PubMed Web of Science ®Google Scholar
• Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA. 2006;103:2352–2357.
   PubMed Web of Science ®Google Scholar
• Saba NS, Liu D, Herman SE, et al. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 2016. 7; 128(1):82–92.
   PubMed Web of Science ®Google Scholar
• Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116:953–961.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Zain JM, Kahl BS, et al. Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies. Am Soc Clin Oncol Educ Book. 2017;37:512–525.
   PubMedGoogle Scholar
• Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle cell lymphoma. J Clin Oncol. 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388(10044):565–575.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355–362.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008;111:558–65 Blood. 2008;111(4):2385–2387.
   PubMedGoogle Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32(13):1338–1346.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530–1533.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Gressin R, Caulet-Maugendre S, Deconinck E, et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Aug;95(8):1350–1357.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the German low grade lymphoma study group. Blood. 2008;111(4):2385–2387.
   PubMed Web of Science ®Google Scholar
• Lim SY, Horsman JM, Hancock BW. The mantle cell lymphoma international prognostic index: does it work in routine practice? Oncol Lett. 2010;1(1):187–188.
   PubMed Web of Science ®Google Scholar
• MIPI: mantle cell lymphoma international prognostic index, European MCL Network; 2016 [cited 2019 Apr 01]. Available from: http://www.european-mcl.net/de/clinical_mipi.php
   Google Scholar
• Hartmann E, Fernandez V, Moreno V, et al. Five‐gene model to predict survival in mantle‐cell lymphoma using frozen or formalin‐fixed, paraffin‐embedded tissue. J Clin Oncol. 2008;26:4966–4972.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119(18):4215–4223.
   PubMed Web of Science ®Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108.
   PubMed Web of Science ®Google Scholar
• Staton AD, Greenwell IB, Switchenko JM, et al. Risk stratification of untreated mantle cell lymphoma patients using MIPI, Ki67 proliferative index and cytogenetics. Blood. 2016;128(22):1785.
   PubMed Web of Science ®Google Scholar
• Cheach CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256–1269.
   PubMed Web of Science ®Google Scholar
• Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol. 2011;29:3023–3029.
   PubMed Web of Science ®Google Scholar
• Hoster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):437–445.
   PubMedGoogle Scholar
• Ferrero S, Dreyling M. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? Haematologica. 2017;102(7):1133–1136.
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. Lymphoma Study Association. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104(1):138–146.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215–3223.
   PubMed Web of Science ®Google Scholar
• Gimenez E, Chauvet M, Rabin L, et al. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang. Br J Haematol. 2012;158(2):186–197.
   PubMed Web of Science ®Google Scholar
• Pott C, Brüggemann M, Ritgen M, et al. MRD detection in B-cell non-hodgkin lymphomas using ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol. 2019;1956:199–228.
   PubMedGoogle Scholar
• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416–3423.
   PubMed Web of Science ®Google Scholar
• Houot R, Le Gouill S, Ojeda Uribe M, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAM. Ann Oncol. 2011;23(6):155–161.
   Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–5316.
   PubMed Web of Science ®Google Scholar
• Wedding U, Ködding D, Pientka L, et al. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol. 2007;64:1–9.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta analysis of controlled trials. Lancet. 1993;342:1032–1036.
   PubMed Web of Science ®Google Scholar
• Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32:19–26.
   PubMed Web of Science ®Google Scholar
• Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26:288–300.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118(13):3377–3386.
   PubMed Web of Science ®Google Scholar
• Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34:2366–2371.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013–7023. 1.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31(11):1442–1449.
   PubMed Web of Science ®Google Scholar
• Branca A, Gianesello I, Brugnaro L, et al. Rituximab-Bendamustine Cytarabine (R-BAC) as frontline therapy in mantle cell lymphoma: a single-center experience. Blood. 2015;126:2710.
   Web of Science ®Google Scholar
• Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15–e23.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Verriere B, Gastaud L, Chamorey E, et al. Description of late onset neutropenia in indolent lymphoma patients treatedwith bendamustine plus rituximab. Hematol Oncol. 2018;36:144–149.
   PubMed Web of Science ®Google Scholar
• Flinn I, van der Jagt R, Chang J, et al. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2017;35:7500.
   Google Scholar
• Sachanas S, Pangalis GA, Vassilakopoulos TP, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011;52:387–393.
   PubMedGoogle Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–1223.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Boumendil A, Finel H, et al. The impact of advanced patient age on mortality after allogeneic hematopoietic celltransplantation for non-hodgkin lymphoma: a retrospective study by the european society for blood and marrow transplantation lymphoma working party. Biol Blood Marrow Transplant. 2018;S1083–8791: 30527–5.
   Google Scholar
• Edwin NC, Kahl B. Evolving treatment strategies in mantle cell lymphoma. Best Pract Res Clin Haematol. 2018;31(3):270–278.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the still NHL7–2008 MAINTAIN trial). J Clin Oncol. 2016;34:7503.
   Web of Science ®Google Scholar
• Visco C, Tisi MC, Evangelista A, et al. Time to progression of matle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185(5):940–944.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Davids MS. Targeting BCL-2 in B-cell lymphomas. Blood. 2017;130(9):1081–1088.
   PubMed Web of Science ®Google Scholar
• Wang M, Popplewell LL, Collins RH Jr, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165:510–518.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
   PubMed Web of Science ®Google Scholar
• Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117:2442–2451.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma. Haematologica. 2018;104(1):138–146.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690–697.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
   PubMed Web of Science ®Google Scholar
• Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;S1470–2045: 30685–5.
   Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed/refractory mantle cell lymphoma: long-term follow-up analysis of the NHL- 003 study. Ann Oncol. 2013;24:2892–2897.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Phase II multicenter study of single agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 “EMERGE” study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170:496–503.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase I/II clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016–2025.
   PubMed Web of Science ®Google Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016;128:1814–182056.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton Tyrosine Kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. 2008;11:32–50.
   Web of Science ®Google Scholar
• Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule SA, Martin P, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–4.
   PubMed Web of Science ®Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48–56.
   PubMed Web of Science ®Google Scholar
• Acalabrutinib prescribing information; 2017 [cited 2018 Nov 12] Available from: https://www.azpicentral.com/calquence/calquence.pdf
   Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–667.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2012;115:2578–2585.
   Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;1:28–39.
   Web of Science ®Google Scholar
• Andorsky DJ, Kolibaba KS, Assouline S, et al. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019;184(2):215–222.
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56:2973–2978.
   PubMed Web of Science ®Google Scholar
• Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992;84:1736–1740.
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119:4597–4607.
   PubMed Web of Science ®Google Scholar
• Mason CE, Di Liberto M, Huang X, et al. Mutation burden in CDKN2C, CDK1 and E2F2 is associated with differential response to targeting CDK4/CDK6 in combination with bortezomib in mantle cell lymphoma. Blood. 2011;118:3738.
   Web of Science ®Google Scholar
• Niesvizky R, Costa LJ, Haideri NA, et al. Preliminary results of a phase 2 study of PD 0332991 in combination with bortezomib and dexamethasone in patients with relapsed and refractory multiple myeloma. Blood. 2011;118:2940.
   PubMed Web of Science ®Google Scholar
• Awan FT, Jurczak W. Use of acalabrutinib in patients with mantle cell lymphoma. Expert Rev Hematol. 2018;11:495–502.
   PubMed Web of Science ®Google Scholar
• Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9:2344–2353.
   PubMed Web of Science ®Google Scholar
• Höring E, Montraveta A, Heine S, et al. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. Br J Haematol. 2017;177:557–561.
   PubMed Web of Science ®Google Scholar
• Ek S, Hogerkorp CM, Dictor M, et al. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 2002;62:4398–4405.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681.
   PubMed Web of Science ®Google Scholar
• Tahir SK, Wass J, Joseph MK, et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther. 2010;9:545–557.
   PubMed Web of Science ®Google Scholar
• Davids MS, von Keudell G, Portell CA, et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol. 2018;36(35):3525–3527.
   Web of Science ®Google Scholar
• Robak T, Smolewski P, Robak P, et al. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leuk Lymphoma. 2019;25:1–13.
   Google Scholar
• Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123(11):1665–1673.
   PubMed Web of Science ®Google Scholar
• Fisher R, Bernstein S, Kahl B, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce A, Smith MR, et al. Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. Blood. 2008;112:264.
   PubMed Web of Science ®Google Scholar
• Seftel MD, Kuruvilla J, Kouroukis T, et al. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leuk Lymphoma. 2017;58:1358–1365.
   PubMed Web of Science ®Google Scholar
• A study of the Bruton’s tyrosine kinase inhibitor Ibrutinib given in combination with Bendamustine and rituximab in patients with newly diagnosed mantle cell. lymphoma. U.S. National Library of Medicine; 2017 [cited 2018 Nov 15. Available from: https://clinicaltrials.gov/ct2/show/NCT01776840
   Google Scholar
• A trial of Ibrutinib, Lenalidomide, and rituximab for patients with relapsed/refractory mantle cell lymphoma (PHILEMON). U.S: National LIbrary of Medicine; 2017 [cited 2018 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02460276
   Google Scholar
• Tam C, Rule S, Le Gouill S, et al. Phase 3 study of ibrutinib in combination with ventoclax in patients with relapsed/refractory mantle cell lymphoma (MCL). Hematol Oncol. 2017;35:421–422.
   Google Scholar
• Enblad G, Karlsson H, Loskog ASI. CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther. 2015;26(8):498–505.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285–295.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–2720.
   PubMed Web of Science ®Google Scholar